Back to results
US 2025/0179184 A1Published application
Foxp1-ablated chimeric cells
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorJose Conejo-Garcia
Life of this patent
Estimating the term…
Abstract
Disclosed herein are non-viral methods to ablate FOXP1 in T cells while effectively expressing chimeric receptors. Therefore, disclosed herein is a chimeric cell expressing a chimeric receptor, wherein the chimeric receptor is encoded by a transgene, and wherein the transgene is inserted in the genome of the cell at a location that disrupts expression or activity of an endogenous FOXP1 protein.
Claims8
A chimeric cell expressing a chimeric receptor,
- wherein the chimeric receptor is encoded by a transgene, and
- wherein the transgene is inserted at a loci within a Foxp1 gene in a genome of a cell thereby disrupting expression or activity of an endogenous Foxp1 protein.
Dependencies are inferred from the claim text.